Skip to main content

Table 3 Characteristics of classical Hodgkin and large B-cell lymphomas in outpatient and inpatient cohorts

From: Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain

 

Classical Hodgkin lymphoma (N = 318)

Large B-cell lymphoma (N = 578)

Characteristic

OPs 1 (n = 216)

IPs 2 (n = 102)

P value 1 vs 2

OPs 1 (n = 369)

IPs 2 (n = 209)

P value 1 vs 2

Age (years), mean (SD)

43.6 (15.8)

51.7 (13.3)

<.001

65.1 (17.5)

69.7 (15.5)

<.001

  < 45, n (%)

113 (52.3)

44 (43.1)

<.001

   

  ≥ 45, n (%)

103 (47.7)

58 (56.9)

<.001

   

  ≤ 60, n (%)

   

121 (32.8)

28 (13.4)

<.001

  > 60, n (%)

   

248 (67.2)

181 (86.6)

<.001

Sex, n (%)

 Females

98 (45.4)

42 (41.2)

.069

156 (42.3)

84 (40.2)

.104

 Males

118 (54.6)

60 (58.8)

.074

213 (57.7)

125 (59.8)

.091

Clinical manifestations, n (%)

      

 Lymphadenopathy

152 (70.4)

51 (50.0)

<.001

246 (66.7)

95 (45.5)

<.001

 Systemic symptoms

51 (23.6)

39 (38.2)

<.001

101 (27.4)

86 (41.1)

<.001

 Pain symptoms

9 (4.2)

8 (7.8)

.084

11 (3.0)

16 (7.7)

.025

 Chest symptoms

3 (1.4)

2 (2.0)

.190

8 (2.2)

8 (3.8)

.120

 Other symptoms/signs

1 (0.0)

2 (2.0)

.131

3 (0.8)

4 (1.9)

.135

Successive/first visit ratio

2.10

  

2.33

  

QDU time for diagnosis /admission time for diagnosis (days), mean (SD)

15.5 (1.7)

11.3 (2.7)

.030

16.7 (2.2)

13 (2.5)

.001

Suspected/compatible lymphoma by FNAC, n (%)/total n

72 (52.9) /136

21 (52.5)/40

.203

156 (71.9)/217

35 (71.4)/49

.155

Time to FNAC (days), mean (SD)

1.3 (0.6)

1.1 (0.4)

.130

1.3 (0.7)

1.2 (0.5)

.125

Time to excisional biopsy (days), mean (SD)

7.3 (1.3)

3.3 (0.9)

<.001

7.1 (1.3)

3.6 (0.9)

.003

ECOG performance score > 1, n (%)/total n

31 (15.6)/199

21 (21.2)/99

.045

70 (20.8)/336

53 (27.5)/193

<.001

B symptoms, n (%)a

68 (31.4)

39 (38.2)

.002

107 (29.0)

71 (34.0)

.021

Serum LDH > UNL, n (%)

30 (13.9)

18 (17.6)

.082

184 (49.9)

119 (56.9)

<.001

Bulky disease, n (%)/total nb

44 (22.4)/196

27 (28.7)/94

.010

86 (24.9)/345

63 (31.5)/200

.001

Extranodal disease, n (%)c

33 (15.3)

20 (19.6)

.061

   

> 1 extranodal site, n (%)

   

99 (26.8)

69 (33.0)

.009

Ann Arbor stage, n (%)

      

 I-II

142 (65.7)

60 (58.8)

.002

157 (42.5)

71 (34.0)

<.001

 III-IV

74 (34.3)

42 (41.2)

.001

212 (57.5)

138 (66.0)

<.001

IPS score (advanced-stage diseasedd), n (%)/total n

      

 Low risk (≤ 3)

166 (84.7)/196

74 (78.7)/94

.035

   

 High risk (≥ 4)

30 (15.3)/196

20 (21.3)/94

.042

   

IPI score, n (%)/total n

      

 Low risk (0-1)

   

114 (33.9)/336

52 (26.9)/193

<.001

 Intermediate risk (2-3)

   

158 (47.0)/336

92 (47.7)/193

.144

 High risk (4-5)

   

64 (19.0)/336

49 (25.4)/193

.004

  1. Abbreviations: OPs total number of outpatients from the quick diagnosis units of the Hospital Clínic and the Hospital of Bellvitge; ECOG Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; UNL upper normal limit; IPS international prognostic score; IPI international prognostic index. For other abbreviations, see Table 1
  2. aRecurrent fever, night sweats, or > 10% weight loss; b ≥ 10 cm largest diameter; cInvolvement of extra lymphatic tissue; dAdvanced-stage disease was defined as stage III or IV disease or stage I or II with bulky disease or stage II disease with B symptoms [59]
  3. For other definitions and explanations, see Table 1 Missing data: variables ‘time to FNAC’ (classical Hodgkin lymphoma: OPs = 5, IPs = 3; large B-cell lymphoma: OPs = 7, IPs = 5), ‘time to excisional biopsy’ (classical Hodgkin lymphoma: OPs = 0, IPs = 1; large B-cell lymphoma: OPs = 3, IPs = 1), ‘B symptoms’ (classical Hodgkin lymphoma: OPs = 2, IPs = 1; large B-cell lymphoma: OPs = 4, IPs = 3)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us